Western blot analysis of extract from HeLa cells untreated or treated with TNF-alpha using NF-kappa;B p105(phospho-Ser907) antibody.
Phospho-NFKB1 (Ser907) Antibody
CSB-PA925652
ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry
Product group Antibodies
ReactivityHuman
TargetNFKB1
Overview
- SupplierCusabio
- Product NamePhospho-NFKB1 (Ser907) Antibody
- Delivery Days Customer20
- ApplicationsWestern Blot, ELISA, ImmunoHistoChemistry
- CertificationResearch Use Only
- ClonalityPolyclonal
- ConjugateUnconjugated
- Gene ID4790
- Target nameNFKB1
- Target descriptionnuclear factor kappa B subunit 1
- Target synonymsCVID12; DNA-binding factor KBF1; EBP-1; KBF1; NFkappaB; NF-kappaB; NF-kappa-B1; NF-kappabeta; NF-kB; NF-kB1; NFKB-p105; NFKB-p50; nuclear factor kappa-B DNA binding subunit; nuclear factor NF-kappa-B p105 subunit; nuclear factor NF-kappa-B p50 subunit; nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
- HostRabbit
- IsotypeIgG
- Protein IDP19838
- Protein NameNuclear factor NF-kappa-B p105 subunit
- Scientific DescriptionNF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5-GGRNNYYCC-3, located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8, NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105. Beg A.A., Baldwin A.S. Jr.Oncogene 9:1487-1492(1994)Guizani-Tabbane L., Ben-Aissa K., Belghith M., Sassi A., Dellagi K.Infect. Immun. 72:2582-2589(2004)Beinke S., Robinson M.J., Hugunin M., Ley S.C.Mol. Cell. Biol. 24:9658-9667(2004)
- ReactivityHuman
- Storage Instruction-20°C or -80°C
- UNSPSC12352203